Clinical trial • Oncology
aHyC-TNBC for Triple negative breast cancer
Clinical trial of aHyC-TNBC for Triple negative breast cancer. 82 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Triple negative breast cancer
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 25-12-2025
- First CTIS Authorization Date
- 31-03-2026
Trial design
Clinical trial across 1 site in Slovenia.
- Target Sample Size
- 82
Eligibility
Recruits 82 Vulnerable population selected; no details on consent or assent handling provided in source..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling provided in source.
Recruitment
- Planned Sample Size
- 82
- Recruitment Window Months
- 48
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 82
Slovenia
- Earliest CTIS Part Ii Submission Date
- 16-02-2026
- Latest Decision Or Authorization Date
- 31-03-2026
- Processing Time Days
- 43
- Number Of Sites
- 1
- Number Of Participants
- 82
Sites
- Site Name
- Institute Of Oncology Ljubljana
- Department Name
- Sektor internistične onkologije
- Principal Investigator Name
- Simona Borštnar
- Principal Investigator Email
- SBorstnar@onko-i.si
- Contact Person Name
- Simona Borštnar
- Contact Person Email
- SBorstnar@onko-i.si
- Number Of Participants
- 82
Sponsor
Primary sponsor
- Full Name
- Celica d.o.o.
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- Slovenia
Investigational products
- Investigational Product Name
- aHyC-TNBC
- Modality
- Cell therapy
Related trials
Other published trials that may interest you.